$ 305 / 10mg
999 in stock (can be backordered)
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to interfere with the FOXO4–p53 protein interaction, enabling targeted elimination of senescent cells in preclinical models. Developed from research at Erasmus University Medical Center, FOXO4-DRI peptide represents a precision approach to senolytic research — selectively inducing apoptosis in aged, dysfunctional cells while sparing healthy cells.
In senescent cells, the FOXO4 transcription factor sequesters p53 in the nucleus, preventing p53-mediated apoptosis and allowing damaged cells to persist. FOXO4-DRI peptide competitively disrupts this interaction, freeing p53 to trigger the intrinsic apoptosis pathway. The D-retro-inverso design provides enhanced proteolytic stability compared to native peptide sequences, allowing effective concentrations to be maintained in research models.
Researchers studying cellular aging and longevity often explore FOXO4-DRI alongside Epithalon for telomerase-activation research and P21 for cell-cycle regulation studies. NAD+ provides a complementary metabolic approach to age-related cellular decline.
Each vial contains FOXO4-DRI peptide manufactured in the USA under ISO-certified conditions. Verified to ≥99% purity by HPLC analysis, with endotoxin screening below 0.1 EU/mg. Certificate of Analysis (COA) available upon request. For laboratory research use only.
FOXO4-DRI is supplied as a lyophilized (freeze-dried) powder to ensure maximum stability of its D-retro-inverso peptide structure. Store unopened vials at -20°C in a dry, light-protected environment. Reconstitute with bacteriostatic water using sterile aseptic technique when ready for experimental use. After reconstitution, store the peptide solution at 2–8°C and use within 28 days to maintain structural integrity and p53-binding activity. Avoid repeated freeze-thaw cycles, as thermal stress can compromise the D-amino-acid backbone that provides this peptide’s enhanced proteolytic resistance. Handle with appropriate laboratory PPE. For research use only.
FOXO4-DRI was developed by Peter L.J. de Keizer and colleagues at Erasmus University Medical Center (Rotterdam, Netherlands), with the landmark study published in Cell in 2017. The research demonstrated that disrupting the FOXO4–p53 interaction selectively induced apoptosis in senescent cells while leaving non-senescent cells unaffected in aging mouse models. The D-retro-inverso (DRI) design approach — using D-amino acids in a reversed sequence to maintain binding topology while resisting protease degradation — was key to achieving sufficient in vivo stability. Since publication, this work has been cited in over 300 peer-reviewed articles and has catalyzed a broader field of senolytic research. Groups at the Buck Institute for Research on Aging, Mayo Clinic, and multiple European universities have built upon these findings. FOXO4-DRI remains one of the most referenced peptide-based senolytics in the aging-research literature. This compound is sold for laboratory research use only.
FOXO4-DRI is a synthetic senolytic peptide that disrupts the FOXO4–p53 protein interaction in senescent cells. By freeing p53, it enables the natural apoptosis pathway to eliminate aged, dysfunctional cells while leaving healthy cells unaffected.
Senescent cells accumulate with age and contribute to tissue dysfunction and chronic inflammation. FOXO4-DRI provides researchers with a precision tool to selectively clear these cells, making it valuable for healthspan, rejuvenation, and age-related disease studies.
Each vial is USA-manufactured under ISO-certified conditions with ≥99% HPLC-verified purity and endotoxin screening below 0.1 EU/mg. COA available. For laboratory research use only.
